Your browser doesn't support javascript.
loading
Identifying the Common Genetic Basis of Antidepressant Response.
Pain, Oliver; Hodgson, Karen; Trubetskoy, Vassily; Ripke, Stephan; Marshe, Victoria S; Adams, Mark J; Byrne, Enda M; Campos, Adrian I; Carrillo-Roa, Tania; Cattaneo, Annamaria; Als, Thomas D; Souery, Daniel; Dernovsek, Mojca Z; Fabbri, Chiara; Hayward, Caroline; Henigsberg, Neven; Hauser, Joanna; Kennedy, James L; Lenze, Eric J; Lewis, Glyn; Müller, Daniel J; Martin, Nicholas G; Mulsant, Benoit H; Mors, Ole; Perroud, Nader; Porteous, David J; Rentería, Miguel E; Reynolds, Charles F; Rietschel, Marcella; Uher, Rudolf; Wigmore, Eleanor M; Maier, Wolfgang; Wray, Naomi R; Aitchison, Katherine J; Arolt, Volker; Baune, Bernhard T; Biernacka, Joanna M; Bondolfi, Guido; Domschke, Katharina; Kato, Masaki; Li, Qingqin S; Liu, Yu-Li; Serretti, Alessandro; Tsai, Shih-Jen; Turecki, Gustavo; Weinshilboum, Richard; McIntosh, Andrew M; Lewis, Cathryn M.
Afiliación
  • Pain O; Social, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
  • Hodgson K; Social, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
  • Trubetskoy V; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Medical Psychology, Berlin, Germany.
  • Ripke S; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Medical Psychology, Berlin, Germany.
  • Marshe VS; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts.
  • Adams MJ; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts.
  • Byrne EM; Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Campos AI; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Carrillo-Roa T; Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
  • Cattaneo A; Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
  • Als TD; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Souery D; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
  • Dernovsek MZ; Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy.
  • Fabbri C; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Hayward C; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus University, Aarhus, Denmark.
  • Henigsberg N; Department of Biomedicine and Centre for Integrative Sequencing (iSEQ), Aarhus University, Aarhus, Denmark.
  • Hauser J; Center for Genomics and Personalized Medicine, Central Region Denmark and Aarhus University, Aarhus, Denmark.
  • Kennedy JL; Laboratoire de Psychologie Medicale, Université Libre de Bruxelles, Brussels, Belgium.
  • Lenze EJ; Centre Européen de Psychologie Medicale (PsyPluriel), Brussels, Belgium.
  • Lewis G; University Psychiatric Clinic, University of Ljubliana, Ljubljana, Slovakia.
  • Müller DJ; Social, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
  • Martin NG; MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom.
  • Mulsant BH; Department of Psychiatry, Croatian Institute for Brain Research, University of Zagreb Medical School, Zagreb, Croatia.
  • Mors O; Psychiatric Genetic Unit, Poznan University of Medical Sciences, Poznan, Poland.
  • Perroud N; Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Porteous DJ; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Rentería ME; Healthy Mind Lab, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Reynolds CF; Division of Psychiatry, University College London, London, United Kingdom.
  • Rietschel M; Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Uher R; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Wigmore EM; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Maier W; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Wray NR; Division of Adult Neurodevelopment and Geriatric Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Aitchison KJ; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Arolt V; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.
  • Baune BT; Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
  • Biernacka JM; Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Bondolfi G; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Domschke K; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Kato M; Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Heidelberg University Faculty of Medicine in Mannheim, Mannheim, Germany.
  • Li QS; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Liu YL; Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
  • Serretti A; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
  • Tsai SJ; Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
  • Turecki G; Department of Psychiatry, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Weinshilboum R; Department of Medical Genetics, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
  • McIntosh AM; Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.
  • Lewis CM; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Biol Psychiatry Glob Open Sci ; 2(2): 115-126, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35712048
Background: Antidepressants are a first-line treatment for depression. However, only a third of individuals experience remission after the first treatment. Common genetic variation, in part, likely regulates antidepressant response, yet the success of previous genome-wide association studies has been limited by sample size. This study performs the largest genetic analysis of prospectively assessed antidepressant response in major depressive disorder to gain insight into the underlying biology and enable out-of-sample prediction. Methods: Genome-wide analysis of remission (n remit = 1852, n nonremit = 3299) and percentage improvement (n = 5218) was performed. Single nucleotide polymorphism-based heritability was estimated using genome-wide complex trait analysis. Genetic covariance with eight mental health phenotypes was estimated using polygenic scores/AVENGEME. Out-of-sample prediction of antidepressant response polygenic scores was assessed. Gene-level association analysis was performed using MAGMA and transcriptome-wide association study. Tissue, pathway, and drug binding enrichment were estimated using MAGMA. Results: Neither genome-wide association study identified genome-wide significant associations. Single nucleotide polymorphism-based heritability was significantly different from zero for remission (h 2 = 0.132, SE = 0.056) but not for percentage improvement (h 2 = -0.018, SE = 0.032). Better antidepressant response was negatively associated with genetic risk for schizophrenia and positively associated with genetic propensity for educational attainment. Leave-one-out validation of antidepressant response polygenic scores demonstrated significant evidence of out-of-sample prediction, though results varied in external cohorts. Gene-based analyses identified ETV4 and DHX8 as significantly associated with antidepressant response. Conclusions: This study demonstrates that antidepressant response is influenced by common genetic variation, has a genetic overlap schizophrenia and educational attainment, and provides a useful resource for future research. Larger sample sizes are required to attain the potential of genetics for understanding and predicting antidepressant response.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Biol Psychiatry Glob Open Sci Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Biol Psychiatry Glob Open Sci Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido